HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART

AIDS

Volumn 21, Issue 16, 2007, Pages 2243-2245

  Soulié, Cathia ^a   Marcelin, Anne Geneviève ^a   Ghosn, Jade ^a   Amellal, Bahia ^a   Assoumou, Lambert ^b   Lambert, Sidonie ^a   Duvivier, Claudine ^a   Costagliola, Dominique ^b   Katlama, Christine ^a   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROVIRUS; VIRUS INHIBITION; VIRUS STRAIN; VIRUS TYPING;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PROVIRUSES; RECEPTORS, CCR5; RECEPTORS, CXCR4; TIME FACTORS; TROPISM; VIRAL LOAD;

EID: 37349009949     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f0e3d0     Document Type: Article

References (19)

1. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4R T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
2. Blaak H, Van't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A 2000; 97:1269-1274.
3. Ostrowski MA, Chun TW, Justement SJ, Motola I, Spinelli MA, Adelsburger J, et al. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 1999; 73:6430-6435.
4. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111-126.
5. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003; 77:7682-7688.
6. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, et al. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 2003; 17:809-814.
7. Galan I, Jimenez JL, Gonzalez-Rivera M, De Jose MI, Navarro M, Ramos JT, et al. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS 2004; 18:247-255.
8. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:382-392.
9. Delobel P, Nugeyre MT, Cazabat M, Sandres-Saune K, Pasquier C, Cuzin L, et al. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol 2006; 80:10229-10236.
10. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728.
11. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004; 17:7-16.
12. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
13. Duvivier C. Lower rate of virological suppression in naive patients initiating HAART with NRTI-sparing regimen compared to standard NRTI-containing regimen: results from Hippocampe - ANRS 121 Trial. In: 10th European AIDS Conference/EACS. Dublin, Ireland. 17-20 November 2005. Abstract PS1/3.
14. Jensen MA, Van't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5:104-112.
15. Beerenwinkel N, Sing T, Lengauer T, Rahnenfuhrer J, Roomp K, Savenkov I, et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005; 21:3943-3950.
16. Burgard M, Chaix ML, Ngo N, Leruez M, Rouzioux C. Real-time HIV-1 PCR for the diagnostic of infection in new borns of African mothers. In: 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. 4-8 February 2001. Abstract no. 243.
17. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
18. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997; 94:1925-1930.
19. Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell LB, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998; 161:3195-3201.